1 / 13

Daclatasvir + Sofosbuvir in HCV GT 1-4 and HIV Coinfection ALLY-2 Study

Explore the efficacy of Daclatasvir and Sofosbuvir for HCV GT 1-4 and HIV coinfection. Results and dosing details from the ALLY-2 trial. Comprehensive analysis for treatment-naïve and experienced patients.

mendezm
Download Presentation

Daclatasvir + Sofosbuvir in HCV GT 1-4 and HIV Coinfection ALLY-2 Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Sofosbuvir in HCV GT 1-4 and HIV CoinfectionALLY-2 Study Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  2. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Study Features Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  3. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Design 0 8 12 20 24 Week Treatment-Naïve N = 101 Daclatasvir + Sofosbuvir SVR12 Treatment-Naïve N = 50 Daclatasvir + Sofosbuvir SVR12 Daclatasvir + Sofosbuvir Treatment-Experienced N = 52 SVR12 Drug DosingDaclatasvir: 60 mg once daily; with efavirenz and nevirapine the dose was increased to 90 mg once daily and with ritonavir-boosted protease inhibitors the dose was decreased to 30 mg once dailySofosbuvir: 400 mg once daily Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  4. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Patient Characteristics Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  5. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: HIV Characteristics Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  6. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 1 SVR12, Genotype 1 31/41 43/44 80/83 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  7. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial:Results SVR12, Genotype 1 and subtypes 31/41 43/44 28/35 32/33 3/6 11/11 80/83 68/71 12/12 n=11 had missing or inconclusive findings for cirrhosis & not included in denominators Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  8. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 1 SVR12, Genotype 1, by Liver Status 70/72 8/9 28/36 2/4 28/28 12/13 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  9. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 2 SVR12, Genotype 2 5/6 2/2 11/11 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  10. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 3 SVR12, Genotype 3 2/3 4/4 6/6 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  11. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 4 SVR12, Genotype 4 No GT4 patients enrolled in this arm 2/2 1/1 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  12. Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Conclusion Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.

  13. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related